FirsthandTech
NASA News ReleasesUnited States2 November 2026

NASA Targets Nov. 29 for Northrop Grumman 25th Space Station Resupply Launch

NASA announced media accreditation details for its 25th Northrop Grumman commercial resupply mission to the International Space Station, targeted to launch no earlier than 10:49 a.m. EST on Nov. 29, 2026. A SpaceX Falcon 9 rocket will launch the Northrop Grumman Cygnus XL spacecraft from Cape Canaveral Space Force Station in Florida. The cargo craft carries crew supplies, food, and scientific research equipment. Ordinary readers might care about the mission because the cargo includes medical experiments that aim to improve drug delivery for cancer and osteoarthritis, as well as treatments for muscle loss linked to aging on Earth. Additionally, the mission delivers a study to help predict if cancer will spread. The Cygnus XL craft will dock with the space station's Unity module until May 2027, supporting ongoing health and physical science research in microgravity. U.S. media representatives must apply for accreditation by Nov. 12, 2026.

What was announced

NASA opened media accreditation for the Northrop Grumman CRS-25 commercial resupply launch. Targeted for no earlier than 10:49 a.m. EST on Sunday, Nov. 29, 2026, the mission will send a Cygnus XL spacecraft to the International Space Station aboard a SpaceX Falcon 9 rocket. Liftoff will take place from Space Launch Complex 40 at Cape Canaveral Space Force Station in Florida. U.S. media citizens must apply by 11:59 p.m. EST on Thursday, Nov. 12, through an online portal.

Once launched, astronauts on the orbital station will grab Cygnus XL using the Canadarm2 robotic arm. They will dock the spacecraft to the Earth-facing port of the Unity module, where it will remain attached until May 2027.

What it means

This launch marks Northrop Grumman's 25th station resupply mission under contract with NASA. Cargo deliveries by commercial contractors maintain regular supplies of food and equipment while supporting long-duration orbital research.

The flight brings specific scientific research projects into orbit. Hardware on board will test manufacturing tiny, DNA-inspired particles designed to improve drug delivery for cancer and osteoarthritis. Researchers will also evaluate human muscle cells alongside medications to study therapeutics for muscle loss caused by spaceflight and normal aging. Another investigation focuses on predicting whether a patient's cancer is likely to spread to other areas of the body. Furthermore, the payload includes a compact radiation sensor intended to protect astronaut health on future deep space missions.

What the announcement does not tell us

The announcement leaves out several operational and technical details. It does not list the specific weight or total mass of the scientific payload, food, and supplies inside the Cygnus XL craft. NASA also does not state which research institutions or pharmaceutical companies developed the onboard medical studies.

The advisory mentions that NASA is shifting resources toward Artemis deep space missions to the Moon and Mars as commercial firms take over low Earth orbit services. However, it does not explain how long NASA plans to continue funding commercial resupply contracts for the International Space Station beyond this mission's scheduled stay through May 2027.

How this was written

This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is NASA News Releases’s own. Always check the original before acting on anything here.

Media accreditation is open for the next launch to deliver NASA science investigations, supplies, and equipment to the International Space Station. A Northrop Grumman Cygnus XL spacecraft will launch in November to the orbital laboratory on a SpaceX Falcon 9 rocket for NASA. The mission is known as NASA’s Northrop Grumman Commercial Resupply Services 25, […]
Source: NASA News Releases

More from NASA News Releases

This content is for informational purposes only and is not professional advice. Specifications, prices, plan tiers, and features change frequently and may differ from what is shown here; verify current details on the manufacturer's or company's official page before purchasing. Ratings are based on analysis of published documentation, not independent lab testing.